There is an increasingly impressive database concerning the possible involvement of cytokines in depression and their role in the therapeutic effects of antidepressants. Based on the discussions which took place on these issues at a recent meeting held in Roscoff, France, this perspective summarizes in a critical way the evidence in favor of such a possibility, and points out the needs for further research to clarify both the nature of the subtle dysregulations that affect neuroendocrine-immune interactions in depressive disorders and their contribution to psychopathology.
Introduction
An international discussion meeting on 'Cytokines, Stress and Depression' in May, 1998 in Roscoff, France brought together a multidisciplinary group of investigators to review the current status of the field. The proceedings of this meeting are in press and serve as a principal reference for this article. 1 This paper derives from the meeting and presents a perspective on the field as perceived by the present authors. Our objective is to briefly examine evidence concerning changes in cytokine expression and activity associated with depression, point out the controversies in the data, state methodological problems in the field that may partly be responsible for the controversies, and suggest research directions that may advance the field.
Evidence strongly suggests that changes in cytokine levels outside the brain cause changes in cytokine expression and activity in the brain. Conversely, cytokine changes in the brain elicit responses outside the brain. This is best understood for proinflammatory cytokines, such as interleukin (IL)-1, tumor necrosis factor alpha (TNF␣) and IL-6. Mechanisms of this bidirectional communication between the brain and the rest of the body are rapidly being discovered. 2 Because of the co-variation in central and peripheral cytokine levels we sometime do not specify in this article the compartment where the change is taking place. 
Cytokines induce behaviors analogous to some symptoms of depression
Support for this hypothesis derives from both human and animal studies. Patients are injected with cytokines such as recombinant IL-2 and interferon-alpha (IFN␣) to treat hepatitis C and certain forms of cancer. These patients typically display anhedonia, helplessness and dysphoria in addition to fatigue, apathy, and mental slowing. 3, 4 In the case of IL-2, depressive symptoms develop within a few days after initiation of the treatment, whereas they require 3-4 weeks of treatment with IFN␣. In this last case, it is now apparent that those patients who become depressed are those who already have a tendency to be depressed before the initiation of the treatment, as assessed by the Montgomery Asberg Depression Rating Scale (MADRS). 5 Neuropsychiatric symptoms spontaneously regress when the cytokine treatment is interrupted.
In laboratory animals, cytokines induce several behavioral alterations that resemble some symptoms of depression. These are anhedonia, decreased food intake, depressed social behavior, psychomotor slowing, and changes in sleep, learning and memory. Some of these changes are associated with hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis and 'glucocorticoid resistance.' They are also observed during chronic immune activation caused by persistent or intermittent infections. Although it is not always easy to distinguish what is due to sickness from what might reflect more specific psychiatric effects, this has been done in the case of two key symptoms of depression, anhedonia and helplessness. Anhedonia is considered as one of the two essential features of a major depressive episode with melancholia. 6 It can be objectively assessed in animals by decreased lever pressing to reward intracranial self-stimulation and a reduced preference for sweet solutions, providing appropriate controls are carried out to discard non specific effects on general activity and fluid intake. IL-1␤, TNF␣, and IL-2 caused in different experimental paradigms 'anhedonia' in rats and mice. 7, 8 Anhedonia was also observed in mice treated with endotoxin, HIV coat protein gp120, influenza virus, mycoplasma fermentans, and in a spontaneously developing systemic autoimmune lupus. [8] [9] [10] In mice with autoimmune lupus, this symptom was reversed by immunosuppressive treatment. Another symptom of depression that has been modeled in animals is helplessness. 'Learned helplessness' refers to learning the lack of contingency between behavior and its consequences. Exposing individual animals to inescapable electric shocks usually induces it. The subject compares the effects of such exposure to the effects of exposure to identical shocks that are escapable, ie, the termination of which is contingent upon the emission of the correct response. Interestingly, inescapable shock induces anhedonic symptoms in animals in the form of a decrease in intracranial self-stimulation and a reduction in preference for sucrose. IL-1 appears to be involved in the development of learned helplessness since blockade of the effects of IL-1 in the brain by intracerebroventricular administration of the IL-1 receptor antagonist abrogated the effects of exposure to inescapable shock, including interference with escape learning. 11 However, other results from the same group question the specificity of the involvement of brain IL-1 in these effects, although the role of other cytokines has not yet been investigated.
It is difficult to compare the effects of cytokine treatment in patients with those occurring in laboratory animals because there are many differences between the two conditions. The cytokines that are administered and the time at which their effects are observed differ from each other. A large variation exists in the type and severity of specific symptoms in patients as compared to animals. Patients injected with cytokines are suffering from cancer or hepatitis whereas animals are by and large, healthy. The behaviors that have been measured and behavioral tests used in humans and animals differ from each other, so much so that the differences sometime preclude direct comparisons. Nevertheless, the available data suggest that cytokines cause changes in behavior of experimental animals that are analogous to symptoms of depression in humans.
Studies on the effects of cytokines on experimental animals and human subjects should be more isomorphic in the future than they are at the present. In addition, the available data from human subjects and animals should be used to elaborate a profile of cytokine-induced affective, behavioral and neurovegetative changes. A profile that is equivalent to this one might then be looked for in depressive states to identify those psychopathological conditions that may involve components of immune activation.
Cytokines induce neuroendocrine changes in animals that appear similar to those in depressed patients
The best-documented changes in all of biological psychiatry are the increase in the activity of the HPA axis and glucocorticoid resistance in depressed patients. 12, 13 At the clinical level, depressed patients have an hyperactive HPA axis, as evidenced by higher levels of CRH in the cerebrospinal fluid, increased plasma cortisol levels, and resistance to the dexamethasone suppression test. In line with the CRH hypothesis of depression, and as proposed by Miller, 13 proinflammatory cytokines might play a causal role in depression mainly because they provide another stimulatory input to the CRH system. Hyperactivity of the brain cytokine system would increase the production of CRH, which would escape the glucocorticoid negative feedback because of the impairment in glucocorticoid receptor translocation from the cytoplasm to the nucleus. At the same time, cytokines would increase the reactivity of the HPA axis to external stressors, by inducing the expression of vasopressin, another ACTH secretagogue, in parvocellular CRH neurons of the paraventricular nucleus of the hypothalamus. 14 The chronically increased CRH drive can by itself alter the production and action of brain cytokines. 15 However, besides the activating effects of cytokines on the HPA axis and their possible involvement in the glucocorticoid resistance that is observed in viral infections and chronic inflammatory states, 13 all of this is still very speculative, and even the possibility that CRH mediates the brain effects of proinflammatory cytokines is not fully supported by the available data. 16 In addition to their stimulating effects on activity of the HPA axis, cytokines enhance secretion of vasopressin and oxytocin and decrease the activities of gonadotropic and somatotropic axes. 17 The way this might be reflected in the neuroendocrine profile of depression has not yet been investigated. Proinflammatory cytokines also induce abnormalities of thyroid hormone concentrations, including low triiodothyronine, thyroxine and thyroid stimulating hormone concentrations. These effects resemble so much those observed in the euthyroid sick syndrome that cytokines are now considered as causal factors in the pathophysiology of this syndrome. 18 Although the hypothalamicpituitary-thyroid alterations that are observed in some depressed patients do not fully mimic the euthyroid sick syndrome, 19 there is recent evidence suggesting that this condition might be more frequent in patients with treatment-resistant depression. 20 Because of the sensitivity of cytokines and neuroendocrine factors to stressful conditions, their interactions are likely to play a pivotal role in adaptation disorders occurring in these conditions. It is now well accepted that untoward life events occurring early in life, eg, child abuse and neglect, loss of parents, increase vulnerability to several major psychiatric disorders, including depression. However, the current emphasis on the possible role of alterations of the HPA axis in the biological substrates of the increased vulnerability of individuals who sustained early trauma has not yet been accompanied by parallel studies on cytokine expression and action in these conditions. The interaction between immune and non-immune stressors has only been studied in the context of cross sensitization, ie, the long-term changes in sensitivity to a stressor produced by previous exposure to a different stressor. Prior exposure of rats to IL-1 was found to sensitize their pituitary-adrenal and autonomic responses to non-immune stressors. 14 This sensitization developed within 3 weeks and was subsumed by the reprogramming of neural circuits and changes in gene expression of constituent neurons.
14 This phenomenon may be clinically relevant in the elderly whose symptoms of depression are often accompanied by infections and inflammation.
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Depression is associated with signs of immune activation
The association of immune changes and depression has been intensely studied in biological psychiatry and represents one of the clinical cornerstones of psychoneuroimmunology. The early enthusiasm for the concept that mental depression is associated with immunosuppression has given way to a more balanced view. Cumulative data summarized in two meta-analytic reviews 22, 23 indicate that depressed patients have a decreased number of lymphocytes, reduced mitogeninduced lymphocyte proliferation, and lowered NK cell activity. 24 However, this is not the whole story. Some depressed patients have increased numbers of white blood cells and neutrophils, increased levels of haptoglobin, a positive acute phase protein, and activated monocytic arm of the immune response. 25, 26 Thus the depressed patients are heterogeneous with respect to the state of their immune system, with some components being suppressed whereas other ones are enhanced. The specificity of these changes is not absolute since some of the immune changes observed in depressed patients have also been reported in patients with other mental disorders. For example, elevated levels of IL-6 and its soluble receptor and biochemical signs of the acute phase reaction have been observed in patients diagnosed with schizophrenia, mania, and post-traumatic stress disorder. Overlapping results such as these are common in biological psychiatry. They question the usefulness of correlating biological variables with disease entities that are exclusively defined by clinical criteria. As pointed out by Irwin, 24 the fact that similar kinds of change in innate and acquired immunity occur in association with several categories of mental disorders supports the possibility that certain shared behavioral or biological characteristics underlie or even mediate the immune changes. A search for these mediators has recently begun. In the case of depression, the diagnosis of melancholia and sleep disturbances appears to moderate the depressed cell mediated immunity. 24 Concerning immune activation, illness severity might be important since increased levels of positive acute phase proteins and enhanced production of cytokines have been more consistently found in melancholic and treatment-resistant depressions than in minor depression. 26 Other important factors are age-of-onset and duration of illness, but not neurovegetative factors, as demonstrated by a recent study carried out in dysthymic and depressive patients differing with respect to neurovegetative characteristics. 27 The experimental counterpart of studies on the relationship between depression and immunity is represented by the investigation of immunological variables in animal models of stress and depression. The literature on the effects of stress on cytokine production and action is quite confusing, due to the wide variety of the types and durations of stressors that have been used, and the methodological problems associated with measures of cytokine synthesis in tissues and cytokine concentrations in biological fluids. 28 Increases as well as decreases or no change in cytokine production have been observed. The few conflicting results that have been obtained in animal models of depression do not make the picture clearer. In the learned helplessness model, rats submitted to inescapable electric shock displayed an increase in IL-1␤ concentrations in certain regions of the central nervous system. 11 However, the specificity of these changes is dubious because rats exposed to inescapable and escapable shocks responded very similarly to each other. Olfactory bulbectomized rats which exhibit several behavioral and neurochemical characteristics qualitatively similar to those found in clinically depressed patients displayed blunted increases in circulating IL-1␤ and TNF-␣ in response to lipopolysaccharide, a cytokine inducer. 29 The anhedonia produced in mice by chronic sequential exposure to a variety of mild stressors was found to be associated with enhanced rather than decreased proliferative response of spleen cells to mitogens.
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Antidepressants apparently interfere with cytokine production and action
If cytokines play a causative role in the pathophysiology of depression then antidepressants should interfere with cytokine production and action. Antidepressants impair the release of proinflammatory cytokines from activated monocytes and macrophages, act as inhibitors of chemotaxis, and enhance the expression of antiinflammatory cytokines. 31 As a typical example, clomipramine, sertraline and trazodone were found in a recent in vitro study to inhibit the stimulated production of IFN-␥, whereas clomipramine and sertraline increased the production of IL-10 in whole blood of healthy volunteers. 32 At the behavioral level, chronic but not acute, antidepressant treatment abrogated LPSinduced anhedonia in rats. 8 This effect was probably mediated by a decreased ability of monocytes and macrophages to produce proinflammatory cytokines. Despite the apparent concordance of the available findings, much more research is needed to address this question. Systematic studies should be conducted on the effects of various classes of antidepressants and non-pharmacological treatments of depression (eg, electroshock) on the different components of sickness induced by LPS or recombinant cytokines. At the clinical level, the effects of antidepressant treatment on immune activation in depressed patients and the temporal relationship between these effects and mood changes should be thoroughly investigated.
Effects of cytokine antagonists on the symptoms of depression should be investigated
If cytokines cause depression then their antagonists acting in the brain should have antidepressant activity. This hypothesis has not been thoroughly tested. We know that centrally administered IL-1 antagonists block learned helplessness in certain conditions 11 and ameliorate decrease in social exploration. 33 Cytokine antagonists with a relatively wide spectrum of action (eg, IL-4 and IL-10 which inhibit the synthesis of several proinflammatory cytokines by activated monocytes) are better suited for this task than more specific cytokine antagonists (eg, IL-1ra, which interferes only with the ability of IL-1␣ and IL-1␤ to bind to their receptors). 34 At the clinical level, therapeutic trials addressing the possible effects of centrally acting anti-inflammatory compounds on depression should be undertaken. The results of these trials are likely to play an important role in shaping the future of the field. In a pilot study designed to objectively evaluate the effects of a single dose of endotoxin on depression, administration of a low dose of LPS significantly improved mood in seven drug-free severely depressed patients the next day following the treatment, at a time when the expression of anti-inflammatory cytokines should be expected to be maximal. 35 However, these changes in mood were transient and dissipated during the next few days.
Biological mechanisms underlying the intersection between cytokines and depression are poorly understood
A causal association between changes in cytokines and depression implies that cytokines are a part of a molecular mechanism underlying depression. However, the exact biological mechanisms of depression remain unknown. Two molecules known to play important roles in depression are serotonin and CRH. As already discussed, cytokines provide one stimulatory input into the CRH system, amongst others, and could thereby be part of an underlying mechanism of depression. Cytokines also affect the catabolism of tryptophan. Serotonin synthesis is dependent on its precursor, tryptophan. Proinflammatory cytokines play a role in the catabolism of tryptophan by enhancing the activity of indoleamine 2,3-deoxygenase (IDO). IDO degrades tryptophan via the kinurenine pathway leading to the synthesis of quinolinic acid. This is physiologically relevant as recently shown by Munn et al. 36 An increase in the expression of brain cytokines in response to systemic immune activation is accompanied by enhanced activity of IDO in microglial cells and increased brain concentrations of quinolinic acid. 37 Thus, changes in cytokines may affect synthesis of serotonin. Moreover, cytokines have been shown to directly interfere with the metabolism of serotonin 15, 38 but the pathophysiological consequence of this effect, if any, has not yet been investigated. Similarly, the effect of antidepressant treatment on cytokine-induced IDO activity is unknown.
Conclusion
The association between cytokines and depression is based on evidence that supports, to various degrees of strength, the following generalizations. These generalizations and the voluminous evidence behind them strongly suggest that the association between cytokine changes and symptoms of depression is unlikely to be merely fortuitous. However, whether or not the association is causative we cannot yet say.
What can be said at the present time is that the intersection between cytokines and depression is a fascinating avatar of the research on neuro-immune interactions. Whether this new field of research will prove important and fruitful for our understanding of the psychopathology of depression is still uncertain. The discovery of the expression of cytokines and cytokine receptors in the brain and the demonstration of their modulation by peripheral and central immune activation has opened new avenues in neurosciences in general, and in neuropharmacology, in particular. The key role played by neuro-immune interactions in mediating adaptive responses to infectious agents raises the possibility that a dysfunction of this regulatory system contributes to the pathogenesis of mental disorders. 2 This may open a new door to therapeutics. Although the neurobiology of depression is certainly not yet ready to make room for an immunology of depression, there is no doubt that previously unseen molecular and cellular players have made their entry on the stage. Their exact role in relation to the other players that are already familiar to psychiatrists still needs clarification, but their mere existence will undoubtedly shape our future views of psychopathology.
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